Online citations, reference lists, and bibliographies.
← Back to Search

Results Of A Phase 2 Clinical Trial At 48 Weeks (AI424-007): A Dose-Ranging, Safety, And Efficacy Comparative Trial Of Atazanavir At Three Doses In Combination With Didanosine And Stavudine In Antiretroviral-Naive Subjects

Ian Sanne, P. Piliero, K. Squires, A. Thiry, S. Schnittman
Published 2003 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Three dose levels of the protease inhibitor (PI) atazanavir (200, 400, and 500 mg once daily) were compared with nelfinavir (750 mg three times daily) when given both as monotherapy and in combination with didanosine and stavudine in 420 antiretroviral-naive subjects infected with HIV-1. Subjects received monotherapy for 2 weeks, followed by combination therapy for 46 weeks. After 48 weeks, mean change from baseline in HIV RNA (−2.57 to −2.33 log10 copies/mL), the proportion of subjects with HIV RNA <400 copies/mL (56%–64%) and <50 copies/mL (28%–42%), and mean increases in CD4 cell count (185–221 cells/mm3) were comparable across treatment groups. Diarrhea was two to three times more common in the nelfinavir group (61% of subjects) than in the atazanavir groups (23%–30% of subjects, p < .0001 versus nelfinavir), and jaundice occurred only in atazanavir-treated subjects (6%, 6%, and 12% in the 200-, 400-, and 500-mg groups, respectively) (p < .03 for all atazanavir regimens vs. nelfinavir). Mean percent change from baseline in fasting low-density lipoprotein (LDL) cholesterol was significantly less in the atazanavir groups (−7% to 4%) than in the nelfinavir group (31%) (p < .0001). In conclusion, once-daily atazanavir is a potent, safe, and well tolerated PI that rapidly and durably suppresses HIV RNA and durably increases CD4 cell count in antiretroviral-naive subjects. Through 48 weeks, atazanavir was not associated with clinically relevant increases in total cholesterol, fasting LDL cholesterol, or fasting triglycerides. In comparison, nelfinavir was associated with prompt, marked, and sustained elevations in these parameters of a magnitude that suggests they are clinically relevant.
This paper references
Overview of patient compliance with medication dosing: a literature review.
R. Greenberg (1984)
10.1001/ARCHDERM.1988.01670020093028
Harrison's Principles of Internal Medicine
J. Bigby (1988)
10.2165/00128413-199208400-00018
HIV-1 protease inhibitors
S. Deeks (1992)
10.1001/JAMA.1993.03500230097036
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
S. Grundy (1993)
10.1016/S0140-6736(05)62505-6
Decline in deaths from AIDS due to new antiretrovirals
R. Hogg (1997)
10.1056/NEJM199709113371101
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
S. Hammer (1997)
10.1056/NEJM199803263381301
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
F. Palella (1998)
10.1016/S0140-6736(05)77774-6
Abnormal fat distribution and use of protease inhibitors
R. Wurtz (1998)
10.1016/S0140-6736(98)03391-1
Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
A. Carr (1998)
10.1056/NEJM199808063390612
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.
S. Michaels (1998)
10.1097/00042560-199806010-00003
Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease.
L. Eldred (1998)
10.1097/00002030-199807000-00003
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
A. Carr (1998)
10.1001/JAMA.279.12.930
A randomized, double-blind trial comparing combinations of Nevirapine, Didanosine, and Zidovudine for HIV-infected patients: the INCAS trial
J. Montaner (1998)
Antiviral activity and resistance profile of an HIV-1 protease inhibitor BMS-232632 [abstract I-79
Y-F Gong (1998)
Pathogenesis of HIV-1protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance
A Carr (1998)
Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.
J. Erickson (1999)
10.1097/01.PAS.0000213299.11649.110
Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy.
G. Moyle (1999)
BMS-232632 : ANTI-HIV HIV-1 PROTEASE INHIBITOR
X. Rabasseda (1999)
10.1097/00002030-199912030-00013
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
R. Haubrich (1999)
10.1097/00002030-199903110-00004
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.
C. Gervasoni (1999)
Lipid abnormalities during saquinavir softgel-based highly active antiretroviral therapy [letter
GJ Moyle (1999)
BMS-232632
X Rabasseda (1999)
BMS-232632: single and multiple oral dose safety and pharmacokinetic study in healthy volunteers [abstract 604
EM O’Mara (1999)
10.1097/00002030-200003310-00005
Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients
A. Monforte (2000)
10.1097/00042560-200001010-00005
Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection
K. Mulligan (2000)
Panel on Clinical Practices for Treatment of HIV Infection
Jean R Anderson (2000)
10.1001/ARCHINTE.160.13.2050
Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.
S. Tsiodras (2000)
10.1097/00042560-200010010-00007
Fat Redistribution in Indinavir‐Treated Patients With HIV Infection: A Review of Postmarketing Cases
Joan O. Benson (2000)
10.1345/aph.19201
Long-Term Patient Adherence to Antiretroviral Therapy
N. Ostrop (2000)
10.1086/317491
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
M. Dubé (2000)
10.7326/0003-4819-133-1-200007040-00004
Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
David Paterson (2000)
10.1080/09540120050123783
The relationship of disease severity, health beliefs and medication adherence among HIV patients
X. Gao (2000)
10.1086/317429
Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
M. Dubé (2000)
10.1080/003655400750045196
Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.
S. Penzak (2000)
10.1097/00002030-200001070-00006
Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
J. Purnell (2000)
10.1128/AAC.44.9.2319-2326.2000
In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632
Yi-Fei Gong (2000)
Safety and antiviral efficacy of a once-daily HIV-1 protease inhibitor BMS-232632: 24-week results from a phase II clinical trial [abstract 691
I Sanne (2000)
Assessment of the effect of uridine diphosphate glucuronosyltransferase (UDP-GT) 1A1 genotype on indirect bilirubin elevations in healthy subjects dosed with BMS-232632 [abstract
EM O’Mara (2000)
BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects [abstract 504
E O’Mara (2000)
10.1310/R8M7-EQ0M-CNPW-39FC
Self-Reported Symptoms After Initiation of a Protease Inhibitor in HIV-Infected Patients and Their Impact on Adherence to HAART
S. Duran (2001)
10.1016/S0016-5085(08)80220-X
Mechanism of indinavir-induced hyperbilirubinemia.
S. Zucker (2001)
10.1080/09540120020018161
Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA
D. Murphy (2001)
10.1016/S0140-6736(00)04056-3
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study
E. Martinez (2001)
10.1007/S11906-001-0011-0
Adverse events, compliance, and changes in therapy
R. Düsing (2001)
10.1097/00019048-200106000-00021
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
S. Grundy (2001)
Adherence to HAART predicts progression in AIDS [abstract 483
DR Bangsberg (2001)
10.1097/00001432-200202000-00005
Hyperlactatemia syndromes in people with HIV infection
M. John (2002)
10.1053/JHEP.2002.32526
Hemolysis and bilirubin conjugation in association with UDP‐glucuronosyltransferase 1A1 promoter polymorphism
M. Kaplan (2002)
The fatty liver in AIDS.
P. Tien (2002)
10.1097/00002030-200203290-00020
The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
P. Piliero (2002)
Atazanavir: a once-daily protease inhibitor with a superior lipid profile. Presented at the XIVth World Congress
P Cahn (2002)
Safety and antiviral efficacy of a novel once-daily HIV-1 protease inhibitor BMS-232632: preliminary results from a phase II clinical trial [abstract 672
I Sanne (2003)
Atazanavir: a once-daily protease inhibitor with a superior lipid profile. Presented at the XIVth World Congress of Cardiology
P Cahn
Adherence to HAART predicts progression in AIDS
D R Bangsberg
Safety and antiviral efficacy of a novel once-daily HIV-1 protease inhibitor BMS-232632: preliminary results from a phase II clinical trial
I Sanne
Safety and antiviral efficacy of a once-daily HIV-1 protease inhibitor BMS-232632: 24-week results from a phase II clinical trial
I Sanne
BMS-232632: single and multiple oral dose safety and pharmacokinetic study in healthy volunteers
E M Oaposmara
BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects
E Oaposmara
AI424-007: 48-week safety and efficacy results from a phase II study of a once-daily HIV-1 protease inhibitor (PI), BMS-232632
K Squires



This paper is referenced by
10.1128/JVI.01479-18
GII.4 Norovirus Protease Shows pH-Sensitive Proteolysis with a Unique Arg-His Pairing in the Catalytic Site
Mariya A Viskovska (2019)
10.1177/0033354917748670
Excess Clinical Comorbidity Among HIV-Infected Patients Accessing Primary Care in US Community Health Centers
K. Mayer (2018)
10.1080/21556660.2018.1535438
A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers
Stephen Youngberg (2018)
10.1038/s41416-018-0201-z
Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?
M. Thompson (2018)
10.1038/s41585-018-0106-x
Nonantibiotic prevention and management of recurrent urinary tract infection
N. Sihra (2018)
10.2147/CMAR.S180345
Clinical outcomes of stereotactic body radiotherapy for de novo pulmonary tumors in patients with completely resected early stage non-small cell lung cancer
Qianqian Zhao (2018)
Valutazione diagnostica e trattamento della dislipidemia nel paziente in terapia HAART
Roberto Manfredi (2017)
10.1007/978-3-319-55849-3_4
Integration of Reaction Kinetics Theory and Gene Expression Programming to Infer Reaction Mechanism
Jason R. White (2017)
10.1016/j.jmii.2015.12.012
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study.
M. Tsai (2017)
Metabolic and Skeletal Complications of HIV Infection
C. Morse (2017)
UvA-DARE ( Digital Academic Repository ) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1
F. Leth (2017)
10.1093/jac/dkw005
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).
Jose R. Castillo-Mancilla (2016)
10.4103/0253-7613.190759
Incidence of atazanavir- associated adverse drug reactions in second -line drugs treated south Indian HIV-1 infected patients
D. Subashini (2016)
10.1111/bcp.13072
Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.
J. Moltó (2016)
Efecto de las concentraciones de ritonavir en la farmacocinética de atazanavir: aplicación de técnicas de modelado y simulación farmacocinético poblacional /
J. A. Gómez (2016)
Syndrome de lipodystrophie associé au VIH : examen des aspects cliniques
Jean-Guy Baril (2016)
10.1097/QAI.0000000000000918
Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059.
Rachel A. Bender Ignacio (2016)
A randomized , controlled trial of initial anti-retroviral therapy with abacavir / lamivudine / zidovudine twice-daily compared to atazanavir once-daily with lamivudine / zidovudine twice-daily in HIV-infected patients over 48 weeks ( ESS 100327 , the ACTION Study )
Princy N. Kumar (2015)
Recomendations from GESIDA/National AIDS plan on antiretroviral therapy in adult patients infected by the human immunodeficiency virus (October 2004)
J. Iribarren (2015)
10.1016/B978-0-7020-6285-8.00152-0
Drugs for HIV infection.
Benjamin Eckhardt (2014)
Insights from an individual-level model of HIV programmes in southern Africa : HIV testing, ART and resistance
V. Cambiano (2014)
10.1016/B978-0-12-382227-7.00101-4
HIV Pharmacogenetics and Pharmacogenomics
C. Wester (2013)
10.1016/B978-1-4557-0101-8.00048-5
Chapter 48 – Manifestations, Mechanisms, and Treatment of HIV-Associated Cardiovascular Disease
D. Lange (2013)
10.1089/aid.2012.0232
Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.
G. Lopardo (2013)
10.1089/AID.2012.0233
Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients.
E. Bissio (2013)
10.4103/0975-1483.104369
Association between Medication Adherence Outcomes and Adverse Drug Reactions to Highly Active Antiretroviral Therapy in Indian Human Immunodeficiency Virus-Positive Patients
R. Rajesh (2012)
10.1089/apc.2011.0092
Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.
C. Mcdonald (2012)
10.1258/ijsa.2012.012047
Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities
E. Seminari (2012)
10.1093/jac/dks152
Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.
J. A. Estévez (2012)
10.1371/journal.pmed.1001290
Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings
T. Campbell (2012)
10.2165/00003495-200767100-00006
Didanosine Enteric-Coated Capsule
S. Moreno (2012)
10.2165/00003495-200666150-00006
Cardiovascular Risk in Patients with HIV Infection
B. Bergersen (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar